Drug Search Results
More Filters [+]

Triclabendazole

Alternative Names: triclabendazole, mp-0274, mp0274, mp 0274, egaten
Latest Update: 2024-07-12
Latest Update Note: Clinical Trial Update

Product Description

Triclabendazole, a benzimidazole derivative, has been routinely used since 1983 in veterinary medicine to control infections with Fasciola spp. in domestic herbivorous animals. (Sourced from: https://pubmed.ncbi.nlm.nih.gov/16307491/)

Mechanisms of Action: Tubulin Inhibitor,Protein Synthesis Inhibitor

Novel Mechanism: No

Modality: Small Molecule

Route of Administration: Intravenous,Oral

FDA Designation: None *

Approval Status: Approved

Approved Countries: Austria | Bangladesh | Dominican Republic | Egypt | France | India | Korea | Malaysia | Pakistan | Slovenia | United Kingdom | United States | Venezuela | Vietnam

Approved Indications: Fascioliasis

Known Adverse Events: Abdominal Pain | Chest Pain | Headache | Pain Unspecified | Hyperhidrosis | Urticaria | Musculoskeletal Pain | Diarrhea

Company: Molecular Partners
Company Location: Z?RICH-SCHLIEREN V8 8952
Company CEO:
Additonal Commercial Interests: None

Clinical Description

Map of Global Clinical Trials for Triclabendazole

Countries in Clinic: Germany, Switzerland, United Kingdom

Active Clinical Trial Count: 1

Highest Development Phases

Phase 1: Oncology Solid Tumor Unspecified

Trial

Phase

Trial Status

Disease

Primary Completion Date

Probability of Success

MP0274-CP101

P1

Completed

Oncology Solid Tumor Unspecified

2021-12-13

27%

Recent News Events